EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
labmate-online.com1d
Automated extraction of metabolites from plant tissue samples: A case study for THCA and terpenoids from cannabis flowers
Tecan’s experience in mass spectrometry and chromatography sample preparation spans from innovative instruments to ...
Daily1d
Takeda gets EMA nod for additional subcutaneous administration of Takhzyro in Hereditary Angioedema patients
Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...
Fijivillage1d
Thousands of people without water again due to turbidity levels
Thousands of people are without water in the Central Division as the heavy rain during Tropical Cyclone Rae has led to an ...
Sandoz Group: Sandoz launches biosimilar Pyzchiva (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the ...
Thoroughbred Daily News4d
HISA Alleges Penn National Vet and 13 Trainers Involved in Joint Injection Conspiracy
An 81-year-old veterinarian and two trainers with decades of experience who were summarily suspended in November by the ...
manilatimes5d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...
PharmiWeb6d
Celltrion expands biosimilar portfolio in the European Union following European Commission approval of two biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to ...